Premium
Serum concentrations of estriol vary widely after application of vaginal oestriol cream
Author(s) -
West Nèvine,
Day Richard,
Graham Garry,
Wright Michael,
White Christopher,
Popovic Gordana,
Moore Kate Hilda
Publication year - 2021
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.14635
Subject(s) - estriol , medicine , pharmacokinetics , serum concentration , confidence interval , postmenopausal women , endocrinology , zoology , hormone , biology
Aims The aim of this study was to establish the pharmacokinetic profile of serum oestriol (E 3 ) concentrations over 24 h following application of vaginal E 3 in chronic users (>12 weeks of E 3 use). The interindividual and intraindividual differences before and after E 3 were examined. Methods Ten women participated. Vaginal cream was omitted for ≥36 h prior to the study days. Blood sampling was performed for E 3 , oestradiol and oestrone concentrations prior to cream application and at 1, 2, 3, 5, 8, 10, 12 and 24 h afterwards. In five women, all samples were repeated on a separate day. Results E 3 was absorbed rapidly in most women. Peak serum E 3 concentration occurred around 2 h (range 1–5 h). The decline in E 3 concentrations was also rapid: falling <100 pmol L −1 in six out of ten women within 8 h and returning to ≤ 10 pmol L −1 at 24 h in nine out of the ten patients. Interindividual variability for peak concentrations was considerable (mean 546 pmol L −1 ; 95% CI 349–743). Area under the concentration–time curve (AUC) values over a dosage interval also varied widely: mean 2145 pmol.h L −1 ; 95% CI 1422–3233. However, repeated measurements in the same woman were highly (peaks: ρ = 0.94) or moderately (AUC: P = 0.74) correlated. Conclusions Postmenopausal E 3 concentrations are negligible. Serum E 3 concentrations of chronic users of E 3 cream varied greatly; however, concentrations declined rapidly within 8 h, generally reaching ‘postmenopausal’ levels by 24 h. The basis for the variation between subjects needs further elucidation. Additional research is required to establish the safety of topical E 3 .